Arbutus Biopharma Ceasing All Discovery Efforts and Discontinuing IM-PROVE III Clinical Trial >ABUS
Arbutus Biopharma Ceasing All Discovery Efforts and Discontinuing IM-PROVE III Clinical Trial >ABUS
arbutus biopharma将停止所有发现工作,并停止Im-PROVE III临床试验> ABUS
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册